There is limited data on concurrent endocrinopathies in patients receiving PD-1 inhibitors with only a few case reports of DKA and hypothyroidism after treatment with a PD-1 inhibitor [10,11]. This evidence concerns the gene PDCD1 and endocrine system disorder.